Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Irritable Bowel Syndrome Overview | 10 | 1 |
| Therapeutics Development | 11 | 1 |
| Pipeline Products for Irritable Bowel Syndrome Overview | 11 | 1 |
| Irritable Bowel Syndrome Therapeutics under Development by Companies | 12 | 2 |
| Irritable Bowel Syndrome Pipeline Products Glance | 14 | 3 |
| Late Stage Products | 14 | 1 |
| Clinical Stage Products | 15 | 1 |
| Early Stage Products | 16 | 1 |
| Irritable Bowel Syndrome Products under Development by Companies | 17 | 2 |
| Irritable Bowel Syndrome Companies Involved in Therapeutics Development | 19 | 23 |
| 4D Pharma Plc | 19 | 1 |
| A. Menarini Industrie Farmaceutiche Riunite Srl | 20 | 1 |
| Alfa Wassermann S.p.A | 21 | 1 |
| Ardelyx, Inc. | 22 | 1 |
| Astellas Pharma Inc. | 23 | 1 |
| CJ HealthCare Corp. | 24 | 1 |
| Dong-A Socio Holdings Co. Ltd. | 25 | 1 |
| Enterome Bioscience SA | 26 | 1 |
| GlaxoSmithKline Plc | 27 | 1 |
| Innovative Med Concepts, LLC | 28 | 1 |
| Ironwood Pharmaceuticals, Inc. | 29 | 1 |
| Kissei Pharmaceutical Co., Ltd. | 30 | 1 |
| Lexicon Pharmaceuticals, Inc. | 31 | 1 |
| Napo Pharmaceuticals Inc | 32 | 1 |
| Ono Pharmaceutical Co., Ltd. | 33 | 1 |
| Pfizer Inc. | 34 | 1 |
| RaQualia Pharma Inc. | 35 | 1 |
| RedHill Biopharma Ltd. | 36 | 1 |
| SK Biopharmaceuticals Co., Ltd. | 37 | 1 |
| Sumitomo Dainippon Pharma Co Ltd | 38 | 1 |
| Synergy Pharmaceuticals, Inc. | 39 | 1 |
| Synthetic Biologics, Inc. | 40 | 1 |
| Vitality Biopharma Inc | 41 | 1 |
| Irritable Bowel Syndrome Therapeutics Assessment | 42 | 11 |
| Assessment by Monotherapy Products | 42 | 1 |
| Assessment by Combination Products | 43 | 1 |
| Assessment by Target | 44 | 2 |
| Assessment by Mechanism of Action | 46 | 3 |
| Assessment by Route of Administration | 49 | 2 |
| Assessment by Molecule Type | 51 | 2 |
| Drug Profiles | 53 | 67 |
| (celecoxib + famciclovir) Drug Profile | 53 | 1 |
| ASP-1017 Drug Profile | 54 | 1 |
| ASP-7147 Drug Profile | 55 | 1 |
| bedoradrine sulfate Drug Profile | 56 | 3 |
| Blautix Drug Profile | 59 | 1 |
| CJ-14199 Drug Profile | 60 | 1 |
| crofelemer DR Drug Profile | 61 | 3 |
| CSTI-300 Drug Profile | 64 | 1 |
| DA-6886 Drug Profile | 65 | 1 |
| DSP-6952 Drug Profile | 66 | 1 |
| EB-420 Drug Profile | 67 | 1 |
| GSK-3179106 Drug Profile | 68 | 1 |
| ibodutant Drug Profile | 69 | 1 |
| linaclotide Drug Profile | 70 | 7 |
| lovastatin Drug Profile | 77 | 4 |
| LT-4006 Drug Profile | 81 | 1 |
| LX-1033 Drug Profile | 82 | 2 |
| ondansetron hydrochloride CR Drug Profile | 84 | 5 |
| ONO-2952 Drug Profile | 89 | 1 |
| ORP-101 Drug Profile | 90 | 1 |
| PBF-677 Drug Profile | 91 | 1 |
| plecanatide Drug Profile | 92 | 8 |
| pregabalin Drug Profile | 100 | 4 |
| relenopride hydrochloride Drug Profile | 104 | 1 |
| rifaximin Drug Profile | 105 | 4 |
| RQ-00202730 Drug Profile | 109 | 1 |
| RQ-00310941 Drug Profile | 110 | 1 |
| Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine Drug Profile | 111 | 1 |
| solabegron hydrochloride Drug Profile | 112 | 2 |
| tenapanor hydrochloride Drug Profile | 114 | 5 |
| VB-210 Drug Profile | 119 | 1 |
| Irritable Bowel Syndrome Dormant Projects | 120 | 5 |
| Irritable Bowel Syndrome Discontinued Products | 125 | 1 |
| Irritable Bowel Syndrome Product Development Milestones | 126 | 13 |
| Featured News &Press Releases | 126 | 1 |
| Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results | 126 | 1 |
| Oct 19, 2016: Ardelyx Announces the Presentation of Positive Global Endpoint Findings from Phase 2b Trial of Tenapanor in Patients with IBS-C at ACG Annual Meeting | 127 | 1 |
| Oct 17, 2016: Synergy Pharmaceuticals Presents Long-Term Data for Plecanatide in Chronic Idiopathic Constipation at the American College of Gastroenterology Annual Scientific Meeting | 128 | 1 |
| Sep 28, 2016: Synergy Pharmaceuticals Announces New Plecanatide Data Presentations at Upcoming Scientific Meeting and Provides Update on IBS-C Program | 129 | 1 |
| Aug 02, 2016: Synthetic Biologics Announces Completion of End of Phase 2 Meeting with FDA for SYN-010, Intended for the Treatment of Irritable Bowel Syndrome with Constipation | 130 | 1 |
| Jul 19, 2016: 4D Pharma Provides Phase I Clinical Trial Update | 130 | 1 |
| Jul 15, 2016: Synergy Pharmaceuticals Provides Update on Ongoing FDA Review of Plecanatide CIC NDA and IBS-C Clinical Development Program | 131 | 1 |
| Jun 20, 2016: RedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA for IBS-D | 132 | 1 |
| May 24, 2016: Synergy Pharmaceuticals Presents New In Vitro Data Showing the pH-Dependent Activity of Plecanatide Replicates That of Naturally Occurring GI Peptide Uroguanylin | 133 | 1 |
| May 23, 2016: Phase I trial Update On Blautix For The Treatment Of Irritable Bowel Syndrome : 4D pharma | 133 | 1 |
| May 23, 2016: Synthetic Biologics Announces Detailed Data from Two SYN-010 Phase 2 Clinical Trials for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) | 134 | 1 |
| May 17, 2016: Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week 2016 | 135 | 1 |
| May 17, 2016: Synthetic Biologics to Host Post-DDW 2016 Conference Call to Recap SYN-010 Phase 2 Clinical Trial Results for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) | 136 | 1 |
| May 16, 2016: Synergy Pharmaceuticals to Present New Plecanatide Data at Digestive Disease Week 2016 | 136 | 1 |
| May 11, 2016: Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development | 137 | 2 |
| Appendix | 139 | 2 |
| Methodology | 139 | 1 |
| Coverage | 139 | 1 |
| Secondary Research | 139 | 1 |
| Primary Research | 139 | 1 |
| Expert Panel Validation | 139 | 1 |
| Contact Us | 139 | 1 |
| Disclaimer | 140 | 1 |